Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The Trump administration implemented a ban on abortion care and counseling services at the Department of Veterans Affairs (VA), affecting veteran patients with reproductive health needs. A veterans advocacy group sued on behalf of affected members, including pregnant veterans with chronic medical conditions. The ban restricts access to healthcare services previously available to eligible veterans.
The Trump administration announced it would withhold $1.3 billion in Medicaid payments to California, citing insufficient state efforts to combat fraud in the public health insurance program. Vice President JD Vance justified the action as necessary to address waste in the program. The withholding directly impacts California's ability to fund Medicaid services and affects millions of beneficiaries relying on the state's healthcare coverage.
A federal appeals court ruled to eliminate telehealth prescribing of mifepristone, a common medication used for abortion and miscarriage care. This action makes it harder for Americans to access the medication and represents a step toward broader abortion restrictions. The decision was made on legal grounds rather than new safety evidence.
The FDA authorized fruit-flavored vapes for adult consumers, reversing years of aggressive regulatory efforts to restrict flavored vaping products. The decision followed pressure from President Trump on FDA leadership. This move eliminates restrictions on flavored e-cigarettes that had been in place to discourage youth vaping.
The Trump administration's changes to CDC vaccine guidance resulted in the loss of recommendations for several vaccines including flu and Covid shots. A judge's stay on these changes created uncertainty about vaccine access in some states, while a halted vaccines committee prevents new recommendations from being made. This directly impacts Americans' access to preventive vaccines and future vaccine development.
The Trump administration redirected the Title X family planning program to de-emphasize hormonal birth control provision at health clinics. This policy shift changes the program's core focus despite clinics receiving delayed funding. The change directly impacts women's access to contraception through federally-funded clinics nationwide.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
Executive Order 14336 directs the establishment and filling of a Strategic Active Pharmaceutical Ingredients Reserve to strengthen domestic pharmaceutical supply chains. The order aims to reduce U.S. dependence on foreign sources for critical drug components and improve resilience against supply disruptions. Americans may see increased availability and potentially lower costs for essential medications through enhanced domestic pharmaceutical production capacity.
President Trump signed Executive Order 14297 to implement Most-Favored-Nation (MFN) pricing for prescription drugs, requiring Medicare to pay no more than the lowest price paid in other developed nations. The order aims to reduce drug costs for American patients and Medicare spending by allowing the government to negotiate lower pharmaceutical prices based on international benchmarks.
Executive Order 14293 signed on May 5, 2025, removes regulatory barriers to increase domestic production of critical medicines in the United States. The order streamlines FDA approval processes and reduces compliance requirements for pharmaceutical manufacturers. This aims to reduce American dependence on foreign drug sources and lower medication costs for consumers.